陈薇团队新冠疫苗海外开展三期临床试验

2020-09-07 央视军事微信公众号 央视军事微信公众号

为了隆重表彰在抗击新冠肺炎疫情斗争中作出杰出贡献的功勋模范人物,张伯礼、张定宇、陈薇被授予“人民英雄”国家荣誉称号。

为了隆重表彰在抗击新冠肺炎疫情斗争中作出杰出贡献的功勋模范人物,张伯礼、张定宇、陈薇被授予“人民英雄”国家荣誉称号。

其中,中国工程院院士、军事科学院军事医学研究院研究员陈薇是其中唯一的军人,过去几十年里,在生物安全领域这个没有硝烟的战场上,陈薇始终冲在一线,出色完成了国家、军队赋予的多项重大任务。

而在武汉战疫的4个月时间里,她率领团队研制的重组新冠疫苗则让世界再次见证了“中国速度”。

武汉战疫

迅速突破核酸检验瓶颈期

新冠肺炎疫情爆发后,由军队抽组的军事医学专家农历大年初二紧急深入武汉,全力进行科研攻关,支援武汉抗击新型冠状病毒感染的肺炎疫情科学研究。陈薇,就是这支队伍的领头雁。

同时间赛跑,与病魔较量。在军事医学专家组刚抵达武汉时,整个武汉市的病毒核酸检测需求非常大,迫切需要提升日检测量。

陈薇带领专家组1天内就完成帐篷式移动检测实验室和检测平台搭建,并利用军事医学研究院自主研制的试剂盒,以及全自动提取核酸的方法,单日标本检测能力最高达到1000份以上,这为武汉核酸检测在遭遇瓶颈期的1月底和2月初,发挥了突出作用。

研发疫苗

已启动三期临床试验

疫苗,是终结新冠肺炎最有力的科技武器。在武汉,陈薇率领团队与北京后方科研基地联合作战,集中力量展开疫苗研制应急科研攻关。

3月16日,陈薇院士团队研制的重组新冠疫苗在武汉启动一期临床试验,这也是全球首个进入临床研究阶段的新冠疫苗。

4月12日,疫苗二期临床试验启动。

8月11日,该疫苗获得国家专利,成为国内首个进入临床获得专利权的新冠疫苗。

目前,该疫苗已获得俄罗斯和巴基斯坦批准开展三期临床试验。

陈薇院士说:“姓军为战,强国为民。我是一名军人,这身军装时刻提醒williamhill asia ,要成为为人民负重前行之人,要成为为人民守护岁月静好的人。要在自己岗位上守土有责、守土尽责,为呵护神州安全、为护航人民的健康和平安作出贡献,这是我一生的追求。”

向抗疫军人致敬!

期待更多好消息!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1748953, encodeId=aa831e489533c, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Thu Jun 17 00:56:05 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030037, encodeId=d84f203003ebd, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Tue Feb 09 09:56:05 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991327, encodeId=a206199132eaa, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Oct 27 06:56:05 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883539, encodeId=a8f4883539d7, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Tue Sep 08 10:22:24 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028519, encodeId=b3ab1028519e2, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Sep 08 02:56:05 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2021-06-17 lishizhe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1748953, encodeId=aa831e489533c, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Thu Jun 17 00:56:05 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030037, encodeId=d84f203003ebd, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Tue Feb 09 09:56:05 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991327, encodeId=a206199132eaa, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Oct 27 06:56:05 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883539, encodeId=a8f4883539d7, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Tue Sep 08 10:22:24 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028519, encodeId=b3ab1028519e2, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Sep 08 02:56:05 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1748953, encodeId=aa831e489533c, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Thu Jun 17 00:56:05 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030037, encodeId=d84f203003ebd, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Tue Feb 09 09:56:05 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991327, encodeId=a206199132eaa, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Oct 27 06:56:05 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883539, encodeId=a8f4883539d7, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Tue Sep 08 10:22:24 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028519, encodeId=b3ab1028519e2, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Sep 08 02:56:05 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1748953, encodeId=aa831e489533c, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Thu Jun 17 00:56:05 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030037, encodeId=d84f203003ebd, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Tue Feb 09 09:56:05 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991327, encodeId=a206199132eaa, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Oct 27 06:56:05 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883539, encodeId=a8f4883539d7, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Tue Sep 08 10:22:24 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028519, encodeId=b3ab1028519e2, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Sep 08 02:56:05 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2020-09-08 ms3000000546723755

    厉害了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1748953, encodeId=aa831e489533c, content=<a href='/topic/show?id=e4d6655811a' target=_blank style='color:#2F92EE;'>#海外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65581, encryptionId=e4d6655811a, topicName=海外)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82fd36209189, createdName=lishizhe, createdTime=Thu Jun 17 00:56:05 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030037, encodeId=d84f203003ebd, content=<a href='/topic/show?id=59d8196e369' target=_blank style='color:#2F92EE;'>#三期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19673, encryptionId=59d8196e369, topicName=三期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0d342500153, createdName=12498bf3m25暂无昵称, createdTime=Tue Feb 09 09:56:05 CST 2021, time=2021-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991327, encodeId=a206199132eaa, content=<a href='/topic/show?id=5bd3196e127' target=_blank style='color:#2F92EE;'>#三期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19671, encryptionId=5bd3196e127, topicName=三期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Tue Oct 27 06:56:05 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883539, encodeId=a8f4883539d7, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04745411455, createdName=ms3000000546723755, createdTime=Tue Sep 08 10:22:24 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1028519, encodeId=b3ab1028519e2, content=新冠肺炎,疫情何时才能消失, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=公卫新人, createdTime=Tue Sep 08 02:56:05 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2020-09-08 公卫新人

    新冠肺炎,疫情何时才能消失

    0

相关威廉亚洲官网

张伯礼:加快新冠病毒疫苗III期临床试验

“疫苗研发是控制新冠肺炎疫情的根本方法,必须加快研发进展,争取早日上市使用。”5月20日,全国人大代表、中国工程院院士、天津中医药大学校长张伯礼告诉记者,他拟在“两

FDA批准抗肿瘤药物IDH1抑制剂HH2301临床试验

上海药物研究所与海和生物联合研发的针对异柠檬酸脱氢酶1(IDH1)突变体的选择性抑制剂HH2301已于近日获得美国食品药品监督管理局(FDA)的临床试验默示许可(IND),拟用于治疗IDH1突变的实体

陈薇团队疫苗研发,还有哪些关卡要闯?

“这些结果是一个重要的里程碑。”军事科学院军事医学研究院生物工程研究所的陈薇院士说。

反转?第一期刊纷纷痛批俄罗斯新冠疫苗存在安全隐患!

Nature、Science纷纷下场评论,这种疫苗可能没有进行大规模试验,是危险的!

关于公开征求《抗肿瘤药联合治疗临床试验技术指导原则》意见的通知

目前抗肿瘤药物联合开发十分活跃。合理的联合治疗可以为肿瘤患者带来更好的治疗选择,但是不恰当的联合开发将增加受试者的风险、降低临床研发效率,浪费时间、财力和医疗资源,反而阻碍了真正有效的联合治疗药物开发